Advances in Therapeutic Options for Pulmonary and Sleep Disorders in Mucopolysaccharidosis (MPS) Patients: A Narrative Review
Advances in Respiratory Medicine · 22.06.2026 · 94 (3) · 41
DOI: 10.3390/arm94030041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Respiratory Medicine, online erschienen am 22.06.2026. Verfasst von Bimaje Akpa. Beteiligte Einrichtung: Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidoses, Sleep Wake Disorders, Lung Diseases. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mucopolysaccharidosis (MPS) are a group of inherited lysosomal storage genetic disorders that affect the body’s ability to break down glycosaminoglycans (GAGs) due to the deficiency of required enzymes. This leads to depositions of these GAGs in various tissues and organs resulting in multi-systemic manifestations including pulmonary and sleep related issues. In recent years, there have been significant advancements in therapeutic options and supportive management which have led to the overall improvement in respiratory care, culminating in improved quality of life for MPS patients. Management of pulmonary and sleep disorders in mucopolysaccharidosis requires a multidisciplinary approach due to the multi-systemic affectation of the genetic disorders. Therapeutic options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) have yielded varying success in mitigating respiratory complications. Emerging treatments such as gene therapies have shown exciting and promising results thus far. Supportive therapies such as airway clearance, regular vaccination and use of positive airway pressure devices are also essential. Pre-operative airway and anesthesia planning is critical to mitigate peri-operative and post-operative complications. Early diagnosis, close monitoring and a patient focused individualized approach are essential for respiratory optimization and overall improvement in clinical outcomes. This review article aims to discuss these advancements in a comprehensive format, making it accessible to medical providers who care for this subset of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
ORCID-Profile: Bimaje Akpa
Zitieren
APA
Akpa, B. (2026). Advances in Therapeutic Options for Pulmonary and Sleep Disorders in Mucopolysaccharidosis (MPS) Patients: A Narrative Review. Advances in Respiratory Medicine, 94(3), 41. https://doi.org/10.3390/arm94030041
Vancouver
Akpa B. Advances in Therapeutic Options for Pulmonary and Sleep Disorders in Mucopolysaccharidosis (MPS) Patients: A Narrative Review. Advances in Respiratory Medicine. 2026;94(3):41. doi:10.3390/arm94030041
BibTeX
@article{Akpa2026,
author = {Akpa, Bimaje},
title = {Advances in Therapeutic Options for Pulmonary and Sleep Disorders in Mucopolysaccharidosis (MPS) Patients: A Narrative Review},
journal = {Advances in Respiratory Medicine},
year = {2026},
volume = {94},
number = {3},
pages = {41},
doi = {10.3390/arm94030041}
}
EUVIMED